ISRCTN45507228CompletedNot Applicable
Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. A 6-year, case-control study.
Hospital of Prato (Italy)0 sites400 target enrollmentStarted: February 26, 2007Last updated:
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 400
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Case patients: consecutive new outpatients with peripheral psoriatic arthritis requiring second-line drugs
- •Controls: consecutive new outpatients with rheumatoid arthritis
Exclusion Criteria
- •Patients with inflammatory spinal pain at presentation or during the disease course, or meeting the modified New York criteria for ankylosing spondylitis, and those with contraindications to the use of traditional DMARDs and anti-TNFa drugs.
Investigators
Similar Trials
Not yet recruiting
Unknown
A study of treatment-free remission in chronic phase chronic myeloid leukemia in combination with asciminib and tyrosine kinase inhibitorsNeoplasmsKCT0009214Gachon University Gil Medical Center69
Active, not recruiting
Phase 1
Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4 or 8 or 12 weeks - Complete RemissionGastroesophageal reflux diseaseMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-004806-25-HUALTANA Pharma AG
Active, not recruiting
Not Applicable
Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4 or 8 or 12 weeks - Complete RemissioGastroesophageal reflux diseaseMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-004806-25-DEALTANA Pharma AG1,200
Active, not recruiting
Not Applicable
Evaluation of the complete remission rates in patients with symptomatic non-erosive reflux disease (NERD) or erosive gastroesophageal reflux disease (GERD) treated with pantoprazole 40 mg o.d. over 4 or 8 or 12 weeks - Complete RemissioGastroesophageal reflux diseaseMedDRA version: 5.0Level: lltClassification code 10038263EUCTR2004-004806-25-ATALTANA Pharma AG1,200
Recruiting
Not Applicable
Predictors of long-term remission in patients with Crohn's disease treated with adalimumabs diseaseCrohn's diseaseJPRN-UMIN000010856Graduate School of Medicine, Chiba University, Department of Gastroenterology and Nephrology (K1)100